• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gamida Cell Ltd (NQ: GMDA )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Gamida Cell Ltd

    < Previous 1 2 3 Next >
    Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
    Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors 
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Issues Update on Israel Operations
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
    From Gamida Cell Ltd.
    Via Business Wire
    First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell to Report Second Quarter 2023 Financial Results
    From Gamida Cell Ltd.
    Via Business Wire
    Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
    From Gamida Cell Ltd.
    Via Business Wire
    Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Appoints Terry Coelho as CFO
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Announces Pricing of $23 Million Public Offering of Securities
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Announces Launch of Public Offering of Securities
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Stock Jumps Over 100% on FDA Approval
    Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight bloo 
    Via MarketBeat
    Exposures Product Safety
    Gamida Cell (NASDAQ: GMDA) Announces its Omisirge Allogeneic Cell Therapy Receives FDA Approval
    Gamida Cell Ltd. (NASDAQ: GMDA) is a biopharma company that is focused on utilizing cell therapy to create innovative therapeutics. 
    Via Spotlight Growth
    Exposures Product Safety
    Promising Upsides on these Biotech Penny Stocks
    These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration. 
    Via MarketBeat
    Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Announces Changes to Board of Directors
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
    From Gamida Cell Ltd.
    Via Business Wire
    Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Announces Closing of $25 Million Financing With Highbridge
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Provides Regulatory Update on Omidubicel
    From Gamida Cell Ltd.
    Via Business Wire
    Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
    From Gamida Cell Ltd.
    Via Business Wire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.